Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1597
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
betamethasone dipropionate (Ointment)
|
| dailymed-instance:dosage |
Apply a thin film of Augmented Betamethasone Dipropionate Ointment to the affected skin areas once or twice daily. Treatment with Augmented Betamethasone Dipropionate Ointment should be limited to 45 g per week. Augmented Betamethasone Dipropionate Ointment is not to be used with occlusive dressings.
|
| dailymed-instance:descripti... |
Augmented Betamethasone Dipropionate Ointment contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17,21-dipropionate ester of betamethasone. Chemically, betamethasone dipropionate is 9-fluoro-11��, 17,21-trihydroxy-16��-methyl-pregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula CHFO, a molecular weight of 504.6, and the following structural formula: Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water. Each gram of Augmented Betamethasone Dipropionate Ointment 0.05% contains: 0.643 mg betamethasone dipropionate, USP (equivalent to 0.5 mg betamethasone), in ACTIBASE, an optimized vehicle of propylene glycol; propylene glycol stearate (55% monoester); white wax; and white petrolatum.
|
| dailymed-instance:clinicalP... |
The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects. Topical corticosteroids, such as betamethasone dipropionate, are effective in the treatment of corticosteroid-responsive dermatoses primarily because of their anti-inflammatory, antipruritic, and vasoconstrictive actions. However, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in each disease are uncertain. Betamethasone dipropionate, a corticosteroid, has been shown to have topical (dermatologic) and systemic pharmacologic and metabolic effects characteristic of this class of drugs.<br/>Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. At 14 g per day, Augmented Betamethasone Dipropionate Ointment was shown to depress the plasma levels of adrenal cortical hormones following repeated application to diseased skin in patients with psoriasis. Adrenal depression in these patients was transient, and rapidly returned to normal upon cessation of treatment. At 7 g per day (3.5 g b.i.d.), Augmented Betamethasone Dipropionate Ointment was shown to cause minimal inhibition of the hypothalamic-pituitary-adrenal (HPA) axis when applied two times daily for 2 to 3 weeks, in normal patients and in patients with psoriasis and eczematous disorders. With 6 g to 7 g of Augmented Betamethasone Dipropionate Ointment applied once daily for 3 weeks, no significant inhibition of the HPA axis was observed in patients with psoriasis and atopic dermatitis, as measured by plasma cortisol and 24-hour urinary 17-hydroxy-corticosteroid levels.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Augmented Betamethasone Dipropionate Ointment is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.
|
| dailymed-instance:supply |
Augmented Betamethasone Dipropionate Ointment 0.05% is supplied in 15-g (NDC 59930-1575-1) and 50-g (NDC 59930-1575-3) tubes; boxes of one. Store at 25��C (77��F); excursions permitted to 15���30��C (59���86��F) [see USP Controlled Room Temperature]
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:overdosag... |
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects.
|
| dailymed-instance:genericMe... |
betamethasone dipropionate
|
| dailymed-instance:fullName |
betamethasone dipropionate (Ointment)
|
| dailymed-instance:adverseRe... |
The local adverse reactions reported with Augmented Betamethasone Dipropionate Ointment applied either once or twice a day during clinical studies are as follows: erythema, 3 per 767 patients; folliculitis, 2 per 767 patients; pruritus, 2 per 767 patients; vesiculation, 1 per 767 patients. The following local adverse reactions are reported infrequently when topical corticosteroids are used as recommended. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria. Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
|
| dailymed-instance:indicatio... |
Augmented Betamethasone Dipropionate Ointment is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
betamethasone dipropionate
|